Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

University of Diyala

Status: Completed

Conditions: Type 2 Diabetes

Treatments: Drug: Empagliflozin/metformin(10/500mg) Oral Tablet; Drug: Sitagliptin/metformin ( 50/500mg) Oral Tablet

Study type: Observational

Funder types: Other

Identifiers

NCT05822674

University of Diyala

Details and patient eligibility

About

A blood glucose level of equal to or greater than 180 mg/dL that occurred during stress in a patient without diabetes mellitus (DM) is termed stress hyperglycemia (SH). The stress hyperglycemia ratio (SHR) is defined as the fasting blood glucose divided by the blood glucose level that is calculated from the glycosylated hemoglobin (HBA1c) value on admission. A significantly higher SHR is associated with worse prognostic biomarkers in diabetic patients with complications

Full description

Stress hyperglycemia (SH) is an increase in circulating glucose levels in biological fluids as a physiological response to stress in diabetic patients who are known or newly diagnosed, or a pathological condition associated with in-hospital-related hyperglycemia.

Interventions. Through their pleiotropic effects, some oral hypoglycemic agents improved stress hyperglycemia. When compared to non-SGLT-I (sodium glucose transporter-inhibitor) users, diabetic patients who used (SGLT-I) and had an acute myocardial infarction had less prevalent stress hyperglycemia, a smaller infarct size, and evidence of a low inflammatory response. The rationale this study is to evaluate the SHR in T2D patients who do not have serious illnesses and are managed with oral hypoglycemic agents

Enrollment: 80 patients

Sex: All

Ages: 35 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥35 years
• Diagnosis of Type 2 diabetes
• Absence of serious illnesses
• No evidence of trauma

Exclusion criteria

• Overt complications of diabetes
• Any participant used antibiotics for infectious diseases
• Any participant used non-steroidal antiinflammatory drugs
• Current or past history of mental diseases
• Current hematological diseases
• Pregnancy
• Nursing mothers

Trial design

80 participants in 2 patient groups

Sitagliptin/metformin

Description:

Patients with T2D treated with sitagliptin/metformin (50/500mg) once daily for 10 weeks

Treatment:

Drug: Sitagliptin/metformin ( 50/500mg) Oral Tablet

Empagliflozin/metformin

Description:

Patients with T2D treated with empagliflozin/metformin (10/500mg) once daily for 10 weeks

Treatment:

Drug: Empagliflozin/metformin(10/500mg) Oral Tablet